GSK struck a licensing and option deal with China’s Frontier Biotechnologies, paying $40 million upfront for two siRNA candidates and agreeing to up to $963 million in milestone payments plus royalties. Frontier has one candidate in Phase 1 in China and another completing IND‑enabling work; GSK will assume global development, regulatory filings and commercialization once milestones are met. The pact underscores big‑pharma appetite for oligonucleotide modalities and China‑originated R&D. A related market move saw additional China‑to‑West licensing activity from Frontier and Harbour, signaling renewed cross‑border dealmaking aimed at accelerating oligo and biologics pipelines into western development channels.